This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $497,002 to The Ohio State University to develop innovative technologies that can effectively target and silence the KRAS gene in colorectal cancer, a difficult-to-treat mutation that commonly leads to metastasis.
The key products and services to be delivered under this 5-year grant include developing an RNA nanotechnology platform to co-deliver a CRISPR-based epigenetic repressor and KRAS-targeted siRNA via engineered exosomes. This multi-pronged approach aims to silence mutant KRAS in primary colorectal tumors and metastatic lung lesions, using advanced in vivo models. The project also involves sub-awards to the University of Houston and University of Kentucky to provide specialized expertise in colorectal cancer biology and preclinical testing. This research seeks to overcome limitations of existing cancer therapies and make progress toward more effective treatments for metastatic colorectal cancer.
Generated 2/25/25, 1:53 AM